iTeos Therapeutics’ (ITOS) “Buy” Rating Reiterated at HC Wainwright

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $46.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 443.74% from the company’s current price.

Several other research analysts also recently issued reports on the stock. JPMorgan Chase & Co. lowered their price target on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Wedbush reaffirmed an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a research report on Tuesday. Finally, Wells Fargo & Company initiated coverage on shares of iTeos Therapeutics in a research report on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 price target on the stock.

iTeos Therapeutics Price Performance

Shares of NASDAQ ITOS opened at $8.46 on Friday. The stock has a market capitalization of $309.04 million, a PE ratio of -2.69 and a beta of 1.39. iTeos Therapeutics has a fifty-two week low of $8.05 and a fifty-two week high of $18.75. The business has a fifty day moving average price of $10.40 and a two-hundred day moving average price of $13.99.

Institutional Investors Weigh In On iTeos Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC bought a new position in shares of iTeos Therapeutics in the 1st quarter worth approximately $3,337,000. Clearline Capital LP bought a new position in shares of iTeos Therapeutics in the 2nd quarter worth approximately $2,328,000. Candriam S.C.A. bought a new stake in shares of iTeos Therapeutics during the 2nd quarter valued at $7,558,000. Kennedy Capital Management LLC purchased a new position in iTeos Therapeutics during the first quarter valued at approximately $1,988,000. Finally, Dimensional Fund Advisors LP increased its stake in iTeos Therapeutics by 14.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock worth $13,481,000 after buying an additional 117,159 shares in the last quarter. Institutional investors own 97.16% of the company’s stock.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.